Alimentiv Translational Research Consortium Symposium


IL-23 Pathway Inhibition in IBD

Register Today

Register Now And We Will Send You A Link.

Event Date
When

May 6, 2021 @ 9:00 am - 12:30 pm EDT, and May 7, 2021 @ 9:00 am - 12:30 pm EDT

Event Details


Watch presentations by our expert presenters and join interactive working sessions.

IL-23 Pathway Inhibition In IBD

This two-half day, virtual educational event is organized for and by members of the Alimentiv Translational Research Consortium to understand the role of IL-23 pathway inhibition in IBD. The Symposium will bring together key stakeholders including gastroenterologists, basic & translational scientists, clinical pharmacologists, trialists and industry sponsors.

Expert Panel

Markus Neurath, MD
Friedrich-Alexander-Universität (FAU), Erlangen-Nürnberg, Germany

Bruce Sands, MD
Mount Sinai, NY, USA

Brian Feagan, MD
Alimentiv Inc., Canada

Wouter de Jonge, PhD
Amsterdam UMC, Netherlands

Clara Abraham, MD
Yale, USA

Harry Sokol, MD, PhD
Sorbonne University, Inserm, France

Joseph Adedokun, MS, RPh
Johnson & Johnson, USA

Lili Cheng, PhD
Protagonist, USA

Maria Abreu, MD
University of Miami, USA

Agenda At A Glance

Agenda for May 6, 2021 (Virtual)

Day 1

  • 9:00 am EDT
    Welcome & Introductions of the Alimentiv Translational Research Consortium
  • Clinical Efficacy & Safety

  • 9:15 am EDT
    State of the Art: Mechanism of Action of IL-23 Blockade

    Markus Neurath, MD, Friedrich-Alexander-Universität (FAU), Erlangen-Nürnberg, Germany

  • 9:40 am EDT
    Efficacy in Inflammatory Bowel Diseases

    Bruce Sands, MD, Mount Sinai, NY, USA

  • 10:05 am EDT
    Safety of IL-23 Blockade

    Brian Feagan, MD, Alimentiv Inc., Canada

  • 10:30 am EDT
    Panel Discussion
  • 10:50 am EDT

    Break (10 min)

  • Clinical Pharmacology & Translational Medicine

  • 11:00 am EDT
    Predictors for Response, Treatment Intensification, and/or Discontinuation

    Wouter de Jonge, PhD, Amsterdam UMC, Netherlands

  • 11:25 am EDT
    Impact of IL-23 Inhibitors on the Mucosal and Systemic Immune System

    Clara Abraham, MD, Yale, USA

  • 11:50 am EDT
    Microbiome Dysbiosis and Cytokine Networks

    Harry Sokol, MD, PhD, Sorbonne University, Inserm, France

  • 12:15 pm EDT
    Panel Discussion
  • 12:30 pm EDT
    Adjourn Until Tomorrow

Agenda for May 7, 2021 (Virtual)

Day 2

  • 9:00 am EDT
    Welcome
  • Drug Design & Development

  • 9:05 am EDT
    Pharmacokinetics & Pharmacodynamics of IL-23 Inhibitors

    Joseph Adedokun, MS, RPh, Johnson & Johnson, USA

  • 9:30 am EDT
    Local vs. Systemic Delivery to Maximize Efficacy

    Lili Cheng, PhD, Protagonist, USA

  • 9:55 am EDT
    Overview of the Pipeline and Strategies for Efficient Drug Development

    Maria Abreu, MD, University of Miami, USA

  • 10:20 am EDT
    Panel Discussion
  • 10:40 am EDT

    Break (15 min)

  • Breakout Session

  • 10:55 am EDT

    Instructions for Breakout Groups

  • 11:00 am EDT

    Working groups to identify areas of translational research that can guide treatment strategies and accelerate further drug development

  • 11:40 am EDT

    Working Group Presentation & General Discussion

  • 12:15 pm EDT

    Summary of Proposed Objectives

  • 12:30 pm EDT
    Meeting Adjourned

Organizing Committee:

Scientific Advisors: